20/20 Biolabs warned on Nasdaq equity, bid price

Q: What Nasdaq listing issues did 20/20 Biolabs (AIDX) disclose?

20/20 Biolabs disclosed noncompliance with Nasdaq’s $1.00 minimum bid price rule and the $2,500,000 stockholders’ equity requirement. Nasdaq has notified the company under Listing Rules 5550(a)(2) (Bid Price Rule) and 5550(b)(1) (Equity Rule).

Q: What is the deadline for AIDX to regain compliance with Nasdaq’s Bid Price Rule?

The compliance period for the Bid Price Rule runs until January 13, 2027. To regain compliance, AIDX’s common stock must have a closing bid price of at least $1.00 per share for at least 10 consecutive business days within this 180-day period.

Q: How far below Nasdaq’s equity requirement is 20/20 Biolabs (AIDX)?

Nasdaq requires $2,500,000 in stockholders’ equity under Listing Rule 5550(b)(1). 20/20 Biolabs reported stockholders’ equity of $1,620,700 as of June 30, 2026, placing it below the required equity level for continued listing.

Q: What timeline does AIDX have to address Nasdaq’s Equity Rule deficiency?

AIDX has 45 calendar days from the September 3, 2026 notification to submit a plan to regain compliance. If Nasdaq accepts the plan, the company may receive up to an additional 180 calendar days to demonstrate compliance.

Q: Can AIDX get a second compliance period for the Bid Price Rule?

A second 180-day Bid Price Rule compliance period may be available if AIDX meets all initial listing standards for The Nasdaq Capital Market, other than the bid price, and provides written notice of its intention to cure. However, it must also regain compliance with the Equity Rule by January 13, 2027 to qualify.

20/20 Biolabs now faces Nasdaq deficiencies on both bid price and equity, with deadlines and potential delisting risk if compliance is not restored.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

8-K

Rhea-AI Filing Summary

20/20 Biolabs, Inc. (AIDX) reports that it has received Nasdaq deficiency notices related to both the minimum bid price and stockholders’ equity listing standards. The company previously entered a 180-day period, ending January 13, 2027, to regain compliance with the $1.00 minimum bid price by maintaining that level for at least 10 consecutive business days. On September 3, 2026, Nasdaq also notified the company that it is below the $2,500,000 stockholders’ equity requirement, after the June 30, 2026 Form 10-Q reported stockholders’ equity of $1,620,700. 20/20 Biolabs has 45 days from the September 3 notice to submit a compliance plan, and may receive up to an additional 180 days if the plan is accepted, but faces potential delisting if it fails to regain compliance.

Positive

None.

Negative

Nasdaq equity deficiency: stockholders’ equity was $1,620,700 versus the $2,500,000 requirement under Listing Rule 5550(b)(1), putting AIDX at risk of delisting if compliance is not restored.
Bid price noncompliance: AIDX remains below the $1.00 minimum bid price and must cure this by January 13, 2027, or its common stock may be delisted from Nasdaq.

Filing Explained

A second Nasdaq cure period for the bid-price deficiency depends on regaining equity compliance by January 13, 2027.

Nasdaq has notified 20/20 Biolabs that it remains out of compliance with both the minimum bid-price rule and the $2,500,000 stockholders’ equity rule, but the notices do not themselves complete a delisting. The company’s common stock is therefore in two active compliance processes with potential listing consequences.

The company has $45 days to submit an equity-compliance plan; if Nasdaq accepts it, Nasdaq may grant up to 180 calendar days from the September 3 notice to show compliance. The existing bid-price period runs through January 13, 2027, but the filing states that failure to regain equity compliance by that date would remove eligibility for an additional bid-price compliance period.

If Nasdaq rejects the equity plan, the company may appeal to a hearings panel. The company says it believes its plan will be sufficient, while also stating that Nasdaq may reject it and that eventual compliance is not assured.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Minimum bid price requirement: $1.00 per share Bid Price compliance period end: January 13, 2027 Nasdaq stockholders’ equity requirement: $2,500,000 +5 more

8 metrics

Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) Bid Price Rule threshold for AIDX common stock

Bid Price compliance period end January 13, 2027 End of initial 180-calendar day period to regain Bid Price Rule compliance

Nasdaq stockholders’ equity requirement $2,500,000 Equity threshold under Nasdaq Listing Rule 5550(b)(1) for continued listing

Reported stockholders’ equity $1,620,700 Stockholders’ equity reported in Form 10-Q for the period ended June 30, 2026

Equity plan submission window 45 days Time from September 3, 2026 Nasdaq equity notice to submit a compliance plan

Potential Equity Rule extension 180 days Maximum extension Nasdaq may grant after accepting a compliance plan

Bid Price compliance business days 10 business days Required consecutive days with closing bid price at or above $1.00

Initial Bid Price deficiency window 30 business days Period from June 3, 2026 to July 16, 2026 when AIDX was below $1.00

Key Terms

Bid Price Rule, Equity Rule, Nasdaq Capital Market, stockholders’ equity, +1 more

5 terms

Bid Price Rule regulatory

"not in compliance with the $1.00 closing bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”)"

Equity Rule regulatory

"not in compliance with the stockholders’ equity requirement of $2,500,000 set forth under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”)"

Nasdaq Capital Market regulatory

"meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

stockholders’ equity financial

"reported stockholders’ equity of $1,620,700, and as of September 3, 2026, the Company does not meet the alternatives for continued listing"

Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.

publicly held shares financial

"required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards"

Shares that are publicly held are portions of a company that any investor can buy or sell on public markets, like slices of a pie owned by many people rather than a few insiders. They matter because they determine how easy it is to trade the stock, influence company control through voting and can affect price swings and dividend payments as supply and demand change in the market.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq listing issues did 20/20 Biolabs (AIDX) disclose?

20/20 Biolabs disclosed noncompliance with Nasdaq’s $1.00 minimum bid price rule and the $2,500,000 stockholders’ equity requirement. Nasdaq has notified the company under Listing Rules 5550(a)(2) (Bid Price Rule) and 5550(b)(1) (Equity Rule).

What is the deadline for AIDX to regain compliance with Nasdaq’s Bid Price Rule?

The compliance period for the Bid Price Rule runs until January 13, 2027. To regain compliance, AIDX’s common stock must have a closing bid price of at least $1.00 per share for at least 10 consecutive business days within this 180-day period.

How far below Nasdaq’s equity requirement is 20/20 Biolabs (AIDX)?

Nasdaq requires $2,500,000 in stockholders’ equity under Listing Rule 5550(b)(1). 20/20 Biolabs reported stockholders’ equity of $1,620,700 as of June 30, 2026, placing it below the required equity level for continued listing.

What timeline does AIDX have to address Nasdaq’s Equity Rule deficiency?

AIDX has 45 calendar days from the September 3, 2026 notification to submit a plan to regain compliance. If Nasdaq accepts the plan, the company may receive up to an additional 180 calendar days to demonstrate compliance.

What happens if 20/20 Biolabs (AIDX) fails to regain Nasdaq compliance?

If AIDX does not regain compliance within the applicable periods, Nasdaq may delist the company’s common stock. The company would receive a delisting notice, and it would have the right to appeal to a hearings panel if a submitted plan is not accepted.

Can AIDX get a second compliance period for the Bid Price Rule?

A second 180-day Bid Price Rule compliance period may be available if AIDX meets all initial listing standards for The Nasdaq Capital Market, other than the bid price, and provides written notice of its intention to cure. However, it must also regain compliance with the Equity Rule by January 13, 2027 to qualify.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/10/2026 - 04:11 PM Accepted by SEC EDGAR 09/10/2026 - 04:10 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2026 (September 3, 2026)

20/20 BIOLABS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-43128		57-2272107
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

15810 Gaither Road, Suite 235, Gaithersburg, MD		20877
(Address of principal executive offices)		(Zip Code)

240-453-6339

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01		AIDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on July 17, 2026, 20/20 Biolabs, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the $1.00 closing bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) for the 30 consecutive business days from June 3, 2026 to July 16, 2026. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was granted a 180-calendar day compliance period, or until January 13, 2027, to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for at least ten (10) consecutive business days during the 180-calendar day compliance period. In the event that the Company is not in compliance by January 13, 2027, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to cure the deficiency and regain compliance with the Bid Price Rule within the compliance period(s) under Nasdaq’s Listing Rules.

On September 3, 2026, the Company received an additional notification letter from Nasdaq indicating that the Company is not in compliance with the stockholders’ equity requirement of $2,500,000 set forth under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”), given that the Company’s Form 10-Q for the period ended June 30, 2026 reported stockholders’ equity of $1,620,700, and as of September 3, 2026, the Company does not meet the alternatives for continued listing. The Company has 45 calendar days to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the notification letter to evidence compliance. If the plan is not accepted, the Company will have the opportunity to appeal that decision to a hearings panel. Although the Company believes that its plan will be sufficient to enable it to regain compliance, no assurance can be provided that Nasdaq will accept the Company’s plan or that the Company will ultimately regain compliance with the Equity Rule. Furthermore, if the Company does not regain compliance with the Equity Rule by January 13, 2027, then the Company will not qualify for an additional 180-calendar day compliance period to regain compliance with the Bid Price Rule.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 10, 2026	20/20 BIOLABS, INC.

	/s/ Jonathan Cohen
	Name:	Jonathan Cohen
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents